Overview

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relative to participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC